flow trial semaglutide kidney outcomes The #FLOW top-line results just dropped showing a 24% reduction in a and cardiovascular composite outcome in #semaglutide treated patients. enrolled 3534 patients with #type2diabetes and #CKD Composite primary flow trial semaglutide chronic kidney

Thigh: Side-by-Side Comparison Professional Weight Loss Support Not sure which injection site is right for you

Same Bicarb Benefits, Easier to Take Traditional bicarb formats ask you to trade GI comfort for performance

severe persistent abdominal pain, sometimes radiating to the back, with or without vomiting Gallbladder disease Acute kidney injury (usually secondary to dehydration from gastrointestinal symptoms) Hypersensitivity reactions Worsening of diabetic retinopathy in patients with pre-existing retinopathy For weight management patients (Zepbound): Monitor for depression or suicidal thoughts Establishing a consistent, sustainable injection schedule is essential for treatment adherence and optimal therapeutic outcomes with tirzepatide

A meta-analysis of 10 trials totaling 71,351 patients extended these findings, showing GLP-1 receptor agonists reduced the composite kidney outcome by 17% across trials